SCHEMBL28068054

SCHEMBL28068054

COc1cc2ccnc(-c3ccc(O)cc3)c2cc1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
APAF1 O14727 1/20 0.44
TDP2 O95551 1/20 0.44
NSD2 O96028 1/20 0.44
CASP3 P42574 1/20 0.44
PPP1CA P62136 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
SAE1 Q9UBE0 1/20 0.44
UBA2 Q9UBT2 1/20 0.44
ESR1 P03372 3/20 0.44
ESR2 Q92731 3/20 0.44
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44
TNF P01375 2/20 0.40
MAOA P21397 1/20 0.40
CYP1A1 P04798 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28068055 0.80 MAOA (0.47) MEN1KMT2AAPAF1TDP2NSD2
SCHEMBL16431665 0.80 APAF1 (0.50) APAF1TDP2NSD2CASP3PPP1CA
SCHEMBL16431829 0.75 APAF1 (0.48) APAF1TDP2NSD2CASP3PPP1CA
SCHEMBL8213907 0.75 CYP3A4 (0.51) APAF1TDP2NSD2CASP3PPP1CA
SCHEMBL30789068 0.74 MEN1 (0.59) MEN1KMT2ATNFCYP1A2CYP3A4
SCHEMBL2460475 0.74 MEN1 (0.66) MEN1KMT2AAPAF1NSD2CASP3
SCHEMBL628689 0.74 APAF1 (0.47) APAF1TDP2NSD2CASP3PPP1CA
SCHEMBL30789071 0.74 MEN1 (0.46) MEN1KMT2ATNFCYP1A2CYP3A4
Bromide SCHEMBL8002743 0.73 MEN1 (0.60) MEN1KMT2ACASP3SENP6PDGFRB
Hydrochloric Acid SCHEMBL1022954 0.73 MEN1 (0.64) MEN1KMT2AAPAF1NSD2CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105636953-A 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions NOVARTIS AG 2016-06-01 CN disclosed